Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PRKDC | P78527 | 11/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890262 | 0.96 | ALOX5 (0.48) | ALOX5PRKDCGGPS1PLA2G2APLA2G4A | |
| SCHEMBL9890269 | 0.94 | PRKDC (0.41) | ALOX5PRKDCGGPS1PIM1CSNK2A2 | |
| SCHEMBL9890265 | 0.92 | ALOX5 (0.51) | ALOX5PRKDCGGPS1PTGES2 | |
| SCHEMBL23433490 | 0.92 | PRKDC (0.46) | ALOX5PRKDCGGPS1PLA2G2APLA2G4A | |
| SCHEMBL22106837 | 0.91 | ALOX5 (0.48) | ALOX5PRKDCGGPS1PLA2G2APLA2G4A | |
| SCHEMBL9890270 | 0.91 | ALOX5 (0.42) | ALOX5PRKDCGGPS1PIM1CSNK2A2 | |
| SCHEMBL17166607 | 0.91 | PRKDC (0.43) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL17228710 | 0.91 | PRKDC (0.43) | ALOX5PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL9890304 | 0.91 | ALOX5 (0.44) | ALOX5PRKDCGGPS1PIM1CSNK2A2 | |
| SCHEMBL22106850 | 0.90 | ALOX5 (0.47) | ALOX5PRKDCGGPS1PLA2G2APLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130020563-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20130020563-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8318323-B2 | Polycyclic compounds and organic electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318323-B2 | Polycyclic compounds and organic electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20120138915-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20100012931-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130020563-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | KCNC1, EED, BMI1 | ALOX5 2756/4885PRKDC 2162/4885GGPS1 1114/4885 |
| US-20100012931-A1 | POLYCYCLIC COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | KCNC1, EED, BMI1 | ALOX5 2756/4885PRKDC 2162/4885GGPS1 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.